Latest Conference Articles

Most studies on the potential of marijuana, classic hallucinogens, 3,4-methylenedioxymethamphetamine, and ketamine have been small with methodological flaws, but the promising results from existing studies suggest that larger studies are warranted, said William M. Suavé, MD, medical director, Greenbrook TMS NeuroHealth Centers, during a presentation on the therapeutic potential of illicit drugs.

During a session at the 2017 Neuroscience Education Institute (NEI) Congress, Ira D. Glick, MD, professor emeritus, Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, emphasized the importance of combining psychological and psychopharmacologic strategies for patients with Axis I disorders and provided guidelines for administering the combination.

Roger S. McIntyre, MD, FRCPC, professor, Departments of Psychiatry and Pharmacology, University of Toronto, and of the Head, Mood Disorders, Psychopharmacology Unit, University Health Network, discussed the contributing factors and effects of misdiagnosing or inappropriately treating patients with antidepressants.

During a session on distinguishing between bipolar disorder and attention-deficit/hyperactivity disorder, David W. Goodman, MD, FAPA, assistant professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, and director and founder, Adult Attention Deficit Disorder Center of Maryland, explained that many of the symptoms for the 2 disorders overlap.

An economic analysis presented at the 2017 Neuroscience Educational Institute (NEI) Congress in Colorado Springs, Colorado, showed that pharmacogenomic testing in patients with specific psychiatric disorders can reduce the utilization of benzodiazepines.

Christi Deaton, PhD, RN, FAHA, FESC, of the University of Cambridge discusses the necessary steps for patients to take in order to prevent cardiovascular conditions.

A panel of doctors at the 2017 Neuroscience Education Institute (NEI) Congress discussed the impact of losing a patient to suicide and how they deal with it.

At the 2017 Neuroscience Education Institute (NEI) Congress, a Friday session focused on the physiology of fear and its impact on wellness. It was presented by Mary D. Moller, PhD, DNP, ARNP, PMHCNS-BC, CPRP, FAAN, associate professor, Pacific Lutheran University School of Nursing, and director of Psychiatric Services, Northwest Center for Integrated Health.

How the president classifies the opioid epidemic matter doesn't matter as much as attention to it and dedication to responding it, said Frank James, MD, JD, of American Society of Addiction Medicine.

A session at the 2017 NEI Congress emphasized the importance of making an accurate diagnosis in patients presenting symptoms of depression.

Only 1 in 3 patients will achieve remission on their first antidepressant, and 67% of patients require 4 antidepressant trials before symptoms remit, said Thomas L. Schwartz, MD, during a session on strategies for switching, combining, or augmenting treatments for patients with major depressive disorder.

There is no known gene for any major psychiatric disorder, nor is one ever likely to be found, explained Stephan M. Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego, during an overview of the age of personalized medicine and the role of pharmacogenetics at a session of the 2017 Neuroscience Education Institute Congress.

Digital health, artificial intelligence and machine learning, and precision medicine are the areas where there is the most excitement in innovations for cardiovascular care, said John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology.

In a Tuesday panel discussion at The American College of Rheumatology’s 2017 Annual Meeting in San Diego, California, representatives from HHS, the National Institutes of Health (NIH), and the CDC outlined ongoing federal initiatives to address the parallel problems of pain and opioid addiction.

On Tuesday afternoon, the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) presented a draft of their new, jointly developed clinical guideline for treating psoriatic arthritis (PsA), at the ACR 2017 Annual Meeting.

In a Tuesday session at the American College of Rheumatology’s 2017 Annual Meeting in San Diego, California, Greg Mertz, MBA, FACMPE, managing director for Physician Strategies Group, LLC, presented a talk title “Value Contracting: Opportunities of Fantasy?” in which he outlined the current landscape for performance-based contracting.

A recap of abstracts presented at The American College of Rheumatology’s 2017 Annual Meeting, including an analysis of data available in an electronic health records database and outcomes and cost effectiveness of sarilumab.

There are a number of environmental factors with significant public health impacts that people don't necessarily think of; for instance, products out in the market haven't necesarily been tested for safety, which comsumers should keep in mind, explained Jeanette Stingone, PhD, of Mount Sinai Health System.

Kamala Nola, PharmD, MS, professor at the Lipscomb University College of Pharmacy, provided an overview of the drugs that have been approved in the past year for the treatment of inflammatory conditions during a session at the 2017 American College of Rheumatology Annual Meeting,

During a session at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, a cardiologist joined rheumatologists to give a detailed look at the relationship between rheumatic conditions and cardiovascular disease.

A panel discussion, titled, "Holy MACRA! How to Survive and Thrive in the New Era of MACRA, MIPS and APMs," was presented on Sunday at the 2017 American College of Rheumatology (ACR) Annual Meeting in San Diego, California.

The title "Reshaping the Relationship Between Physicians and PBMs" suggested that the Sunday session at the 2017 American College of Rheumatology’s Annual Meeting in San Diego, California, would focus on reconciling the goals of providers and pharmacy benefit managers (PBMs), but physicians’ challenges in dealing with PBMs quickly became the primary focus of the panel discussion.

Among the most anticipated sessions at the 2017 meeting of the American College of Rheumatology in San Diego, California was “The Great Debate: Biosimilars…to Switch, or Not to Switch? That Is the Question.”

The healthcare industry is getting better at creating value-based drug pricing arrangements, and even if they never dominate the market, there will always be a place for these contracts, said Ira Klein, MD, MBA, FACP, senior director of healthcare quality strategy for the Strategic Customer Group at Janssen Pharmaceuticals.

The biggest challenges in promoting cardiovascular prevention strategies is motivating people to change a lifetime of poor habits into healthier habits, explained Christi Deaton, PhD, RN, FAHA, FESC, of the University of Cambridge.

During the final panel at the fall meeting of the ACO & Emerging Healthcare Delivery Coalition® in Nashville, Tennessee, panelists discussed the progress specialties have made in moving to value-based payment models, as well as the challenges facing the industry as a whole. The panel consisted of 3 individuals who provided perspectives from specific specialties, and 1 with an overall policy perspective.

Improving treatment for addiction means first recognizing that addiction is a chronic disease and also understanding that relapse is part of the disease process, explained Frank James, MD, JD, of American Society of Addiction Medicine.

There have been tremendous improvements in healthcare quality and performance measurements, but one area where more needs to be done is incorporating social risk factors into these measurements, said Shantanu Agrawal, MD, CEO and president of National Quality Forum.